MOR208
Author: Zachary McLellan
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
MorphoSys is positioning its cluster of differentiation (CD)19-targeted monoclonal antibody MOR208 in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant. MOR208 has shown strong response rates in these patients in the Phase II L-MIND study, similar to those observed with chimeric antigen receptor T-cell (CAR-T) therapies, which have become a significant addition to the DLBCL treatment paradigm. MOR208 will compete with CAR-T regimens in these heavily pretreated patients and will be aided by a relatively cheap cost and improved side-effect profile. In addition, MOR208 is currently being evaluated in the Phase II/III B-MIND study (ClinicalTrials.gov identifier: NCT02763319) against the standard of care, Rituxan (rituximab; Biogen/Roche/Chugai/Zenyaku Kogyo). A demonstrated survival improvement in this trial would further improve MOR208’s outlook in this indication.
Analyst Outlook
MorphoSys is positioning its cluster of differentiation (CD)19-targeted monoclonal antibody (MAb) MOR208 in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who are ineligible for high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT). MOR208 has shown strong response rates in these patients in the Phase II L-MIND study (ClinicalTrials.gov identifier: NCT02399085), similar to those observed with chimeric antigen receptor T-cell (CAR-T) therapies, which have become a significant addition to the DLBCL treatment paradigm. MOR208 will compete with CAR-T regimens in these heavily pretreated patients and will be aided by a relatively cheap cost and improved side-effect profile. In addition, MOR208 is currently being evaluated in the Phase II/III B-MIND study (ClinicalTrials.gov identifier: NCT02763319) against the standard of care, Rituxan (rituximab; Biogen/Roche/Chugai/Zenyaku Kogyo). A demonstrated survival improvement in this trial would further improve MOR208’s outlook in this indication.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 MOR208 : NHL: Diffuse large B-cell lymphoma (DLBCL)
LIST OF FIGURES
10 Figure 1: MOR208 for diffuse large B-cell lymphoma – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary for MOR208 in diffuse large B-cell lymphoma
12 Figure 3: Datamonitor Healthcare’s drug assessment summary for MOR208 in diffuse large B-cell lymphoma
14 Figure 4: MOR208 sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country, 2017–26
LIST OF TABLES
6 Table 1: MOR208 drug profile
7 Table 2: MOR208 ongoing pivotal trial in diffuse large B-cell lymphoma
9 Table 3: Early-phase data for MOR208 in diffuse large B-cell lymphoma
15 Table 4: MOR208 sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
polatuzumab vedotin 
Sign up to the